FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Sachdev Amit			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below))				Owner (specify
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED			3. Date of Earliest Transaction (Month/Day/Year) 02/24/2021								below) EVF	P, Chief P	below atient Office	· I
50 NORTHERN AVENUE (Street)		4.	If Amendi	ment, Da	te of O	riginal	Filed (Month/	Day/Yea		Line)		·	Filing (Check	··
` '	2210									X		led by Mor	e Reporting Per e than One Re	
(City) (State) (2	Zip)													
Table	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Ye	ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d 5) Secur Benef Owner		icially d Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)	(Instr. 4)	(Instr. 4)
Common Stock	02/24/202	1			F		2,946	D	\$217	'.57	43,	,719	D	
Common Stock	02/25/202	1	L		S ⁽¹⁾		922	D	\$211.5	56 ⁽²⁾⁽³⁾ 42		,797	D	
Common Stock	02/25/202	1					1,460	D	\$213.3	3(3)(4) 4:		,337	D	
Common Stock	02/25/202	1					668	D	\$214.1	19 ⁽³⁾⁽⁵⁾ 40		,669	D	
Common Stock	02/25/202	1					336	D	\$215.5	5.56 ⁽³⁾⁽⁶⁾		,333	D	
Common Stock	02/25/202	1					200	D	\$216	5.62	40,	40,133		
Common Stock												82	I	401(k)
Common Stock											7,3	368	I	Held in trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
L. Title of Derivative Security Instr. 3) 2. Conversion or Exercise Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year)			Transaction of Code (Instr. De		Expiratio (Month/D			Ame Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		vative d urity S tr. 5) B C F	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
Evaluation of Donnance		Cod	le V	(A) (E	Da Da	te ercisal	Expiration Date	on Title	Numbe of					

Explanation of Responses:

- 1. Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$211.56 (range \$211.06 to \$211.87).
- 3. Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$213.30 (range \$212.93 to \$213.88).
- 5. Open market sales reported on this line occurred at a weighted average price of \$214.19 (range \$213.94 to \$214.78).
- 6. Open market sales reported on this line occurred at a weighted average price of \$215.56 (range \$215.12 to \$215.85).

Remarks:

/s/ Sabrina Yohai, Attorney-in-02/26/2021 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.